SCHEDULE 13G
Amendment No. 0
FATE THERAPEUTICS INC
Common Stock
Cusip #31189P102
Cusip #31189P102
Item 1: Reporting Person - FMR LLC
Item 4: Delaware
Item 5: 0
Item 6: 0
Item 7: 3,053,573
Item 8: 0
Item 9: 3,053,573
Item 11: 15.000%
Item 12: HC
Cusip #31189P102
Item 1: Reporting Person - Edward C. Johnson 3d
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 3,053,573
Item 8: 0
Item 9: 3,053,573
Item 11: 15.000%
Item 12: IN
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
Item 1(a). Name of Issuer:
FATE THERAPEUTICS INC
Item 1(b). Name of Issuer's Principal Executive Offices:
3535 General Atomics Court
Ste 200
San Diego, CA 92121
USA
Item 2(a). Name of Person Filing:
FMR LLC
Item 2(b). Address or Principal Business Office or, if None,
Residence:
245 Summer Street,Boston,Massachusetts 02210
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP Number:
31189P102
Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b)
and the person filing,
FMR LLC, is a parent holding company in accordance with Section 240.13d-
1(b)(ii)(G). (Note: See Item 7).
Item 4. Ownership
(a) Amount Beneficially Owned: 3,053,573
(b) Percent of Class: 15.000%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 3,053,573
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Various persons have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of, the
Common Stock of FATE THERAPEUTICS INC. The interest of one person, Fidelity
Growth Company Fund, an investment company registered under the Investment
Company Act of 1940, in the Common Stock of FATE THERAPEUTICS INC, amounted
to 1,526,787 shares or 7.500% of the total outstanding Common Stock at
October 31, 2013. The interest of one person, Select Biotechnology
Portfolio, an investment company registered under the Investment Company
Act of 1940, in the Common Stock of FATE THERAPEUTICS INC, amounted to
1,381,284 shares or 6.785% of the total outstanding Common Stock at October
31, 2013.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
See attached Exhibit A.
Item 8. Identification and Classification of Members of the Group.
Not applicable. See attached Exhibit A.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the
effect of changing or influencing the control of the issuer of such
securities and were not acquired in connection with or as a participant in
any transaction having such purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
November 8, 2013
Date
/s/ Scott C. Goebel
Signature
Scott C. Goebel
Duly authorized under Power of Attorney effective as of June 1, 2008,
by and on behalf of FMR LLC and its direct and indirect subsidiaries
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
Pursuant to the instructions in Item 7 of Schedule 13G,
Fidelity Management & Research Company ("Fidelity"), 245 Summer Street,
Boston, Massachusetts 02210, a wholly-owned subsidiary of FMR LLC and an
investment adviser registered under Section 203 of the Investment Advisers
Act of 1940, is the beneficial owner of 1,526,787 shares or 7.500% of the
Common Stock outstanding of FATE THERAPEUTICS INC ("the Company") as a
result of acting as investment adviser to various investment companies
registered under Section 8 of the investment Company Act of 1940.
The ownership of one investment company, Fidelity Growth
Company Fund, amounted to 1,526,787 shares or 7.500% of the Common Stock
outstanding. Fidelity Growth Company Fund has its principal business office
at 245 Summer Street, Boston, Massachusetts 02210.
Edward C. Johnson 3d and FMR LLC, through its control of
Fidelity, and the funds each has sole power to dispose of the 1,526,787
shares owned by the Funds.
Fidelity SelectCo, LLC ("SelectCo"), 1225 17th Street,
Suite 1100, Denver, Colorado 80202, a wholly-owned subsidiary of FMR LLC
and an investment adviser registered under Section 203 of the Investment
Advisers Act of 1940, is the beneficial owner of 1,526,786 shares or
7.5000% of the outstanding Common Stock outstanding of FATE THERAPETICS
INC ("the Company") as a result of acting as investment adviser
to various investment companies registered under Section 8 of the
Investment Company Act of 1940 (the "SelectCo Funds").
The ownership of one investment company, Select
Biotechnology Portfolio, amounted to 1,381,284 shares or 6.785% of the
Common Stock outstanding. Select Biotechnology Portfolio has its principal
business office at 245 Summer Street, Boston, Massachusetts 02210.
Edward C. Johnson 3d and FMR LLC, through its control
of SelectCo, and the SelectCo Funds each has sole power to dispose of
the 1,526,786 shares owned by the SelectCo Funds.
Members of the family of Edward C. Johnson 3d, Chairman of
FMR LLC, are the predominant owners, directly or through trusts, of Series
B voting common shares of FMR LLC, representing 49% of the voting power of
FMR LLC. The Johnson family group and all other Series B shareholders have
entered into a shareholders' voting agreement under which all Series B
voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of
voting common shares and the execution of the shareholders' voting
agreement, members of the Johnson family may be deemed, under the
Investment Company Act of 1940, to form a controlling group with respect to
FMR LLC.
Neither FMR LLC nor Edward C. Johnson 3d, Chairman of FMR
LLC, has the sole power to vote or direct the voting of the shares owned
directly by the Fidelity Funds, which power resides with the Funds' Boards
of Trustees. Fidelity carries out the voting of the shares under written
guidelines established by the Funds' Boards of Trustees.
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
RULE 13d-1(f)(1) AGREEMENT
The undersigned persons, on November 8, 2013, agree and
consent to the joint filing on their behalf of this Schedule 13G in
connection with their beneficial ownership of the Common Stock of FATE
THERAPEUTICS INC at October 31, 2013.
FMR LLC
By /s/ Scott C. Goebel
Scott C. Goebel
Duly authorized under Power of Attorney effective as of June 1, 2008, by
and on behalf of FMR LLC and its direct and indirect subsidiaries
Edward C. Johnson 3d
By /s/ Scott C. Goebel
Scott C. Goebel
Duly authorized under Power of Attorney effective as of June 1, 2008, by
and on behalf of Edward C. Johnson 3d
Fidelity Management & Research Company
By /s/ Scott C. Goebel
Scott C. Goebel
Senior V.P. and General Counsel
Fidelity Growth Company Fund
By /s/ Scott C. Goebel
Scott C. Goebel
Secretary
Select Biotechnology Portfolio
By /s/ Scott C. Goebel
Scott C. Goebel
Secretary